07:58 AM EDT, 10/09/2024 (MT Newswires) -- Viatris ( VTRS ) said Wednesday its phase 3 trial in Japan evaluating EFFEXOR for generalized anxiety disorder met its primary objective, showing superiority over placebo in reducing anxiety symptoms at eight weeks.

The trial, which assessed 804 patients, met primary and all secondary efficacy endpoints, Viatris ( VTRS ) said. EFFEXOR was generally well tolerated, with low discontinuation rates and no severe treatment-emergent adverse events, it added.

Viatris ( VTRS ) shares were up 0.7% in recent premarket activity.

Price: 11.40, Change: +0.08, Percent Change: +0.71